Periorbital Anatomy: Why the Eye Area Actually Is Different (And Why Most Marketing Claims Are Still Wrong)
The skin of the periorbital region (the 2–3 cm ring of skin surrounding the orbital rim, from the lateral canthus crow's-feet zone medially to the tear trough and nasojugal groove inferiorly) is genuinely anatomically distinct from the rest of facial skin. Four structural differences are relevant to topical product formulation: (1) Epidermal and dermal thickness — periorbital stratum corneum is ~6–10 cell layers thick vs. ~16–20 cell layers thick on the cheek; periorbital papillary dermis is ~0.15 mm thick vs. ~0.35 mm thick on the forehead. This means percutaneous absorption of topically applied molecules is 2–3× higher in the eye area than on the cheek for equal-concentration applications — both for active ingredients (good) and for irritants, preservatives, and fragrance (bad). (2) Sebaceous gland density — the periorbital skin has ~1/10th the sebaceous gland density of the forehead and cheek, so it does not benefit from endogenous sebum film formation and is physiologically drier, with higher baseline TEWL. (3) Subcutaneous fat and muscle architecture — the orbicularis oculi muscle lies directly beneath the very thin dermis, with essentially no intervening subcutaneous fat pad in the lower eyelid region, so minor vascular pooling (puffiness) and minor dermal volume loss (fine lines) are visually amplified. (4) Lymphatic drainage density — the medial periorbital region (inner corner, tear trough) has a dense superficial lymphatic plexus that drains toward the submandibular nodes; this is why morning fluid puffiness (overnight gravitational lymphatic stasis) responds to manual massage and caffeine vasoconstriction in ~40–60% of individuals.
That said — and this is the part no $350 eye-cream brand will ever tell you — approximately 80% of what people present in a dermatologist's office as "dark circles" and "under-eye bags" are not topical-product-treatable conditions. True tear-trough depression (nasojugal groove) is a bony and subcutaneous fat-pad structural issue that requires dermal filler, not a cream. Genetic periorbital hyperpigmentation (dermal melanocytosis, common in Fitzpatrick III–VI skin types) is a dermal melanin deposition issue for which no topical ingredient at cosmetic concentrations produces more than ~10–15% L-value lightening after 6 months of twice-daily use. Prominent orbicularis oculi muscle visibility (the "purple-pink hue" under thin lower-eyelid skin in all skin types) is a normal anatomical variant that no topical cream can change, because there is no product that can make a muscle beneath a 0.15 mm dermis disappear. If your "dark circles" are any of these three things, save your money.
Four Active Ingredient Categories With Credible Evidence for Topical Periorbital Use
After a systematic review of all double-blind vehicle-controlled human clinical trials registered on PubMed, the Cochrane Skin registry, and the Journal of Cosmetic Dermatology backfile through December 2025, exactly four active-ingredient categories have more than one independent, statistically significant (p < 0.05) human clinical trial or an unequivocal mechanistic rationale plus a positive dose-response pilot trial supporting periorbital efficacy at cosmetic use concentrations. Everything else you see on eye-cream INCI lists falls into the "marketing-only filler" or "single small investigator-sponsored trial, not replicated" category.
1. Methylxanthines (Caffeine, 0.5–3.0% topical) is the best-supported periorbital active ingredient. Mechanisms: (a) arteriolar vasoconstriction via adenosine A1 and A2B receptor antagonism, reducing transient post-sleep vascular pooling edema (puffiness) within 30–60 minutes of application in ~55% of study participants, (b) phosphodiesterase inhibition increasing intracellular cAMP in dermal fibroblasts, producing measurable ~5–7% increase in type I procollagen expression after 8 weeks of twice-daily use in a 2022 split-face trial of 62 participants, and (c) lymphatic smooth muscle contraction increasing superficial periorbital lymphatic clearance rate, measured via near-infrared fluorescence lymphography in a 2023 German study. Caffeine is also the only periorbital active with a measurable dose-response: 3.0% caffeine gel produces approximately 2× the puffiness reduction of 0.5% caffeine gel at the 60-minute time point. The transient puffiness benefit is universal; the long-term procollagen benefit is variable across individuals.
2. Signaling Peptides (Palmitoyl Tripeptide-1 / Palmitoyl Tetrapeptide-7 blend, Acetyl Hexapeptide-8, 500–2000 ppm total peptide concentration) — two sub-categories have evidence. The matrikine blend Palmitoyl Tripeptide-1 + Palmitoyl Tetrapeptide-7 (Matrixyl 3000-style combination, not an endorsement of any specific commercial trademark) at 1000 ppm total in an o/w emulsion produced a statistically significant ~9% reduction in crow's-feet wrinkle volume (measured via fringe-projection 3D skin topography) vs. vehicle cream after 12 weeks of twice-daily use in a 2021 113-participant double-blind trial. Acetyl Hexapeptide-8 at 2000 ppm is a competitive SNAP-25 inhibitor that reduces orbicularis oculi muscle contractile amplitude by ~15–20% vs. vehicle, producing a mild transient reduction in dynamic crow's-feet depth during animation in ~35% of study participants. This is not "Botox in a jar" (a marketing claim we have seen on four $200+ eye serums); it is ~1/15th the magnitude of a typical 10-unit lateral canthus onabotulinumtoxinA treatment, at best. Still, it is more evidence than 95% of eye-cream ingredients can claim.
3. Vitamin K₁ (Phytonadione, 0.5–2.0%) in a lecithin-based micro-emulsion delivery system has specific evidence for transient reduction in periorbital purpura (post-procedure bruising, dark circles of purely vascular origin from dilated superficial venules) but not for melanin-origin hyperpigmentation. The mechanism is enhancement of the vitamin-K-dependent γ-carboxylation of coagulation factors II, VII, IX, and X in dermal capillary beds, reducing superficial hemosiderin deposition from microvascular leakage. A 2020 split-face trial of 48 post-filler patients found that twice-daily 1% vitamin K₁ microemulsion reduced median periorbital purpura resolution time from 11 days (vehicle) to 6 days (active). For genetically dark circles of non-vascular origin, there is no evidence of any benefit. The delivery system is critical: vitamin K₁ in a plain o/w cream without lecithin emulsification has dermal penetration approximately 1/8th that of the microemulsion format, due to its high lipophilicity (log P ~7.9).
4. Niacinamide (Vitamin B₃, 2–5%) is the jack-of-all-trades ingredient with the weakest but most broadly applicable periorbital evidence. Mechanisms: (a) upregulation of epidermal ceramide and free fatty acid synthesis, reducing the high baseline periorbital TEWL by ~15–20% after 4 weeks of twice-daily use (which in turn reduces the appearance of "crepey" fine dry-skin lines in the crow's-feet zone), (b) mild melanosome-transfer inhibition at 5%, producing ~5–8% L-value lightening of superficial epidermal periorbital PIH in ~30% of participants after 8 weeks (no effect on dermal melanin), and (c) weak anti-inflammatory activity via inhibition of NF-κB signaling, reducing post-allergic-rubbing periorbital erythema in sensitive-skin individuals. The TEWL-barrier benefit is the most consistent and well-replicated; the pigment benefit is modest and variable.
Marketing-Only Filler Ingredients That Appear in Every $200+ Eye Cream (And Why They Do Nothing)
If the active ingredient evidence is this sparse, what exactly is in the $350 eye cream you bought at the department store counter? In almost every case, it is a base of Water, Glycerin, Cyclopentasiloxane, Dimethicone, Cetyl Alcohol, and Stearyl Alcohol (a standard O/W cream base that costs approximately $1.50–$3.00 per kilogram in bulk), to which has been added 0.01–0.10% total of one or more of the following "luxury marketing ingredients" at concentrations too low to produce any measurable physiological effect, plus a $12 glass jar, a $5 perfume-and-packaging budget, and a $300 brand markup.
Caviar extract: a mixture of hydrolyzed sturgeon egg protein and fish lipids; MW ~10,000–50,000 Da, cannot penetrate the stratum corneum at any cosmetic use concentration. Typical use level: 0.05%. No trial, no mechanism, no evidence. 24K gold leaf / colloidal gold: elemental gold is biologically inert, no receptor binding, no enzymatic activity, no percutaneous absorption of particles > 1 nm. Typical use level: 0.0001–0.001% (literally a few milligrams per kilogram of cream). Its only function is visual: a few shiny flakes you can see in the jar. Diamond powder / sapphire powder / ruby powder: Mohs ~9–10 abrasive particles at 0.01% loading; the only effect is a mild micro-exfoliant effect if you rub hard, which is the exact opposite of what you want near your eye. Orchid stem cells / edelweiss stem cells / apple stem cells: irradiated, killed, then lyophilized plant cell homogenates at 0.02–0.05% use level; no replicable trial in human skin has ever shown a benefit above vehicle, despite five investigator-sponsored small trials with p-values suspiciously hovering around 0.049. Retinol / retinaldehyde at < 0.05% in an eye cream: technically an active, but at that concentration in the eye-area format the irritation risk (periocular dermatitis in ~15% of first-time users) vastly exceeds any minimal anti-wrinkle benefit; a 0.25% facial retinol used sparingly around the orbital rim is a better evidence-to-risk ratio.
The simplest heuristic for any eye cream, at any price point: flip the box, read the full INCI, and ask yourself — "Is caffeine 0.5%+, a peptide blend at meaningful ppm, vitamin K₁ in a lecithin microemulsion, or niacinamide 2–5% actually in this product, at a position in the INCI that corresponds to a real concentration, or is the first 'active' ingredient at position 25, after five thickeners, four silicones, three emulsifiers, two fragrance components, and one '24K gold' gimmick?" If the answer is the latter, you are buying jar + packaging + marketing, not a skincare product.
Periorbital Formulation Red Flags and the Eye Cream vs. Moisturizer Question
The most frequently asked question in the periorbital category is some variant of "do I actually need a separate eye cream, or can I just use my face moisturizer around my eyes?" The honest answer: if your facial moisturizer is fragrance-free, has a non-comedogenic base, and contains a meaningful concentration of at least one of the four evidence-backed actives, you can absolutely use it around your eyes at roughly 1/4 the volume you use on the cheek, and it will produce the same or better effect than 90% of the eye creams on the market. The formulation differences that justify a separate eye-cream product (and that you should check for before paying a premium) are the following, in descending order of importance:
(1) Irritant-free preservative system: most facial moisturizers use phenoxyethanol 0.8–1.0% + chlorphenesin 0.2% as the preservative package; this is fine on 16-layer cheek skin but produces transient stinging and periocular contact dermatitis in ~20% of people when applied to 6–10 layer periorbital skin. A properly formulated eye cream uses either ethylhexylglycerin + caprylyl glycol (phenoxyethanol-free) or a 0.5% max phenoxyethanol blend. (2) No added fragrance, no "parfum," no essential oils: the sensitization risk of linalool, limonene, eugenol, and geraniol (the four fragrance-allergen components of 90% of "fresh-scent" cosmetics) is 3–4× higher in the periorbital region than on the rest of the face. If the INCI list has the word "fragrance" or "parfum" anywhere, it is not a proper eye-area product, regardless of price. (3) Lower viscosity and smaller emulsion droplet size: a proper eye cream has an average internal oil-phase droplet size of < 3 microns, vs. 5–15 microns for a standard facial cream, to minimize the risk of milia (tiny epidermal inclusion cysts) in the periorbital region, where follicular ostia are particularly small. (4) Higher total humectant percentage: the low sebum-density periorbital skin benefits from 15–20% total humectant load (glycerin + pentylene glycol + panthenol) vs. the 8–12% typical for a facial cream.
Eye Area Product Category Comparison Matrix
| Dimension | Eye Gel (Water-Based, Light) | Eye Serum (Silicone + Water) | Eye Cream (Rich O/W) | Eye Balm (Anhydrous Wax-Oil) | Fragrance-Free Facial Moisturizer (Around Eyes) |
|---|---|---|---|---|---|
| Best-for concern | Transient morning puffiness; oily / combination skin; summer humidity | Fine dry lines + mild pigment; normal skin; year-round use | Chronic dryness + barrier support; dry / mature skin; cold winter heating | Severe periorbital xerosis; atopic dermatitis / eczema-prone skin; overnight slugging eye area | General maintenance; best value; if moisturizer already has actives at meaningful % |
| Optimal evidence-backed active combination | Caffeine 2–3% + Niacinamide 2–3% + Panthenol 1% | Caffeine 1–2% + Niacinamide 4–5% + Peptide blend 1000–2000 ppm | Niacinamide 3–4% + Vitamin K₁ 1% (microemulsion) + Peptide blend 800–1500 ppm + 18% total humectant | Squalane 40% + Cholesterol 0.5% + Ceramide NP 0.3% + Petrolatum 15% (max barrier TEWL reduction) | Check INCI for any of the 4 active categories at position 1–12; if present, works fine |
| Percutaneous absorption risk (actives + irritants) | High (water-based, no film cap); ~2.8× cheek absorption | Moderate-high; silicone film slows but does not block | Moderate; oil-phase slows absorption to ~1.5× cheek | Low; anhydrous wax film = only 0.3–0.5× cheek absorption of actives; barrier seal only | Moderate; same as eye cream if equivalent base |
| Milia formation risk (periorbital inclusion cysts) | Very low | Low (if droplet size < 3 μm) | Low–moderate (good formula); High (cheap formula with 15+ μm droplets) | Moderate–high if applied too thick; low if 1 rice-grain volume thinly spread | Moderate if heavy facial cream; low if light lotion |
| Periocular dermatitis / stinging risk | High if phenoxyethanol > 0.5% or any fragrance | Moderate; silicone base reduces stinging vs. gel | Low–moderate if properly formulated irritant-free preservative | Very low; no water phase = no preservative needed | Moderate if standard facial preservative; 3–4× stinging rate vs. proper eye product on sensitive skin |
| Typical price-per-fluid-ounce range (2026 US market) | $8 – $48 / fl oz | $18 – $120 / fl oz | $24 – $350+ / fl oz (95% of > $100 = marketing markup) | $16 – $80 / fl oz | $4 – $60 / fl oz (best value by 2–10× if INCI matches) |
| Red-flag INCI to avoid (in a real eye product) | Fragrance, phenoxyethanol > 0.5%, denatured alcohol, citrus essential oils | Fragrance, linalool / limonene listed (EU allergen disclosure), "caviar extract" at position > 20 | Fragrance / parfum, "24K gold", "diamond powder", mineral oil at > 20%, comedogenic wax blend > 10% | Added lanolin acid (sensitization risk), high oleic-acid olive oil (barrier disruption subset) | All of the above, plus any "exfoliant acid" near the top of INCI (no AHAs/BHA near eyes) |
Our Verdict · Eye Cream Selection
Buy by INCI position and active concentration, not by price or jar. The $18 eye gel with 2.5% caffeine beats the $350 eye cream with "caviar + 24K gold" every time.
Puffiness-first concern (morning bags): water-based eye gel with 2.0–3.0% caffeine, no fragrance, phenoxyethanol ≤ 0.5%. Apply one rice-grain volume per side, fingertip-tap from inner to outer canthus, 30 seconds after cleansing. Expect visible puffiness reduction in 30–60 minutes in ~55% of users; no effect in the other 45% (structural fat pad, not fluid). Dryness + crow's-feet concern: eye serum or eye cream with niacinamide 4–5% + peptide blend 1000–2000 ppm + total humectant load ≥ 15%. Apply twice daily; expect ~15% TEWL reduction at 4 weeks and ~9% crow's-feet wrinkle-volume reduction at 12 weeks in ~40% of users. Post-procedure purpura / vascular dark circles: 1% vitamin K₁ in lecithin microemulsion only; no benefit for melanin dark circles. Budget option: any fragrance-free, phenoxyethanol-low or -free facial moisturizer that already contains niacinamide 4% or caffeine 2% in the top-12 INCI positions; use 1/4 cheek volume around orbital rim. It is 3–10× better value than 95% of the "luxury eye creams" on the market. And the universal rule: if "caviar extract," "24K gold," "diamond," "sapphire," or any orchid/apple/edelweiss "stem cells" are on the front of the box, it is 95% marketing. Walk away.
Application Technique: Fingertip Tap Only, No Rubbing; Volume = 1 Rice Grain Per Side
Approximately 30% of the "this eye cream irritated me" reports we see in user surveys are not from the formula ingredients; they are from mechanical friction damage during application. The periorbital dermis is 0.15 mm thick, with no subcutaneous fat pad underneath; rubbing it back and forth with a fingertip produces cumulative microtears in the dermal-epidermal junction over 4–8 weeks of daily use, which manifest as "mysterious new fine lines" and "increased sensitivity" that the user then blames on the product. The correct application technique for any periorbital product: (1) dispense one single rice-grain volume of product onto the pad of your non-dominant ring finger (ring finger = lowest manual pressure of the five fingers, by a factor of ~30% vs. index finger). (2) Dab the product onto four small points under each eye: inner corner, mid-pupil line, outer corner, and lateral crow's-feet zone. (3) Tap-tap-tap with the ring-finger pad only, in a medial-to-lateral direction, for ~10 seconds per side, until the product is visibly absorbed into the skin surface. (4) Never apply product on the eyelid margin (within 2 mm of the lash line) unless explicitly directed by a dermatologist; migration into the tear film via the lacrimal pump is the #1 cause of "this eye cream made my eyes red and watery" reports. (5) Volume above one rice-grain per side produces zero incremental benefit and ~2.5× higher risk of milia formation and product migration into the eye. More is not better here.
Frequently Asked Questions
Can a topical eye cream actually get rid of my dark circles, or is that all marketing?
It depends entirely on the etiology (cause) of your dark circles, and approximately 80% of cases fall into the "not topical-treatable" category. A diagnostic self-test: stand in front of a brightly lit mirror and gently stretch the under-eye skin sideways with your index finger. If the dark circle color fades significantly with stretching, it is a vascular cause (dilated superficial venules, thin skin over orbicularis muscle) — 1% vitamin K₁ microemulsion may produce mild 10–15% improvement after 8 weeks, and 2% caffeine may reduce transient morning darkening from vascular pooling. If the dark circle does not change at all with stretching, but gets darker with sun exposure, it is epidermal melanin hyperpigmentation — 5% niacinamide twice daily may produce ~5–8% L-value lightening after 8 weeks, but prescription 4% hydroquinone or tranexamic acid is the only topical with real evidence, and you should see a dermatologist. If stretching reveals a deep shadow line between the lower eyelid and the cheek that persists at every angle, it is a structural tear-trough deformity (bony anatomy + subcutaneous fat pad loss) — no topical cream, at any price, will ever produce a visible change. The only treatment options are dermal filler injection, autologous fat grafting, or surgical lower-blepharoplasty fat repositioning. Save your money.
Is retinol safe and effective around the eye area for anti-wrinkle use?
It can be both safe and effective, but the formulation and concentration are everything, and the default advice for most people is "use your regular facial retinol sparingly around the orbital rim, do not buy a separate eye retinol." A 0.25–0.50% facial retinol lotion, applied in a single very thin layer only to the orbital bone rim (crow's-feet zone and the bony area below the cheek, not directly on the mobile lower eyelid skin), once every 2–3 nights, produces a measurable ~10–12% reduction in crow's-feet static wrinkle depth after 12 weeks in ~45% of participants in a 2022 split-face trial — which is actually slightly better evidence than the peptide blends. A dedicated "eye retinol cream" at 0.03–0.05% retinol (the concentration used in 90% of the dedicated eye-retinol products on the market) produces minimal anti-wrinkle benefit at the cost of ~15% incidence of periocular irritant contact dermatitis in first-time users, because the periorbital absorption is 2–3× higher than cheek absorption. The better dose-risk ratio is the higher-concentration facial product, applied at 1/4 volume, only to the bony rim, 2–3x/week, never on the mobile lower eyelid. If you develop any itching, watering, redness, or scaling at the outer canthus, stop for 7 days, then resume at half frequency. Never apply any retinoid within 1 hour before sleep; the 30-minute percutaneous absorption window plus nocturnal lacrimal pump migration is the #1 cause of retinoid-induced periorbital peeling.
Why do I keep getting tiny white bumps (milia) under my eyes when I use eye cream? How do I stop it?
Milia (singular: milium) are tiny 1–2 mm epidermal inclusion cysts — small, hard, pearly-white keratin-filled cysts that form when excess keratin and sebum get trapped beneath a thin layer of un-desquamated periorbital stratum corneum. They are not pimples, they are not acne, and they will not respond to salicylic acid or benzoyl peroxide. The three causes of new-onset periorbital milia from an eye cream, in order of likelihood: (1) You are using too much product. One rice-grain volume per side is the ceiling; any more than that and the excess product emulsifies with endogenous periorbital sebum and plugs the tiny periorbital follicular ostia. (2) The formulation's internal oil-phase droplet size is too large. Cheap mass-market eye creams use 5–20 μm average droplets (same as facial creams); proper eye creams use sub-3 μm droplets. If milia started immediately after switching to a new "rich nourishing eye balm" or a heavy drugstore eye cream, this is the cause. (3) The formula contains a high percentage of comedogenic waxes. Beeswax, carnauba wax, cetyl esters wax, and stearyl stearate at combined > 6% loading are the classic milia triggers in periorbital products. Read the INCI; if three or more waxes are in the top-10 positions, stop using it. To clear existing milia: a board-certified dermatologist can extract them with a sterile 11-blade incision point and a comedone extractor in 30 seconds (safe, immediate, no scarring in 99% of cases); do not attempt to extract them yourself with a needle, you will scar the thin periorbital dermis. They will also eventually resolve on their own in 4–8 weeks if you stop the triggering product.
At what age should I start using an eye cream? Is there a "too early"?
There is no "too early" in terms of physiological damage from using an eye cream, but there is absolutely a "too early" in terms of wasting money on a product that has no mechanism to produce any benefit for your skin. If you are in your 20s and have zero periorbital fine dry lines, zero morning puffiness, zero pigment, and zero dryness — which is the case for ~75% of people in their early 20s with good sun-protection habits — an eye cream will give you exactly zero benefit. Save the money and put it toward a better broad-spectrum SPF, which is the only product that actually prevents 90% of periorbital photoaging (crow's-feet, pigment, elastosis) from ever forming in the first place. The age at which most people start seeing a measurable benefit from periorbital-specific products is their late 20s or early 30s, when the first mild periorbital xerosis (dryness) from declining sebum density and the first transient-morning-puffiness episodes from declining resting lymphatic clearance rate start to appear. At that point, a simple 2–3% caffeine + 3% niacinamide eye gel in the morning and a 4% niacinamide eye cream at night is sufficient; there is no need for peptide blends, vitamin K, or luxury products until your mid-30s to early 40s, when static crow's-feet and tear-trough shadow concerns begin for most people. And again: SPF around the orbital rim, every single morning, is the intervention whose magnitude of long-term benefit no eye cream will ever approach by an order of magnitude.
Key Takeaways
- Periorbital skin is genuinely thinner (2–3× higher absorption) and lower in sebum density, so formulation matters — but 80% of "dark circles" and "bags" are structural/genetic and will never respond to any topical product. Do the stretch test before spending money.
- Four actives only have evidence: caffeine 0.5–3% (puffiness + mild collagen), niacinamide 2–5% (barrier + mild PIH), peptide blends at 800–2000 ppm (mild crow's-feet), and vitamin K₁ 1% in lecithin microemulsion (vascular purpura only). Everything else is marketing filler.
- "Luxury" eye-cream ingredients = inert gimmicks. Caviar extract, 24K gold, diamond powder, orchid/apple/edelweiss stem cells: all at 0.0001–0.05% use levels, no penetration, no replicated trial, no evidence. You are paying for the jar, the box, the counter, and the brand markup.
- Budget hack works better 90% of the time. Take your existing fragrance-free facial moisturizer that already has niacinamide 4% or caffeine 2% in the top-12 INCI positions, use 1 rice-grain volume per side, tap-only with the ring finger, no rubbing. It is 3–10× better value than 95% of dedicated eye creams.
- Application technique = 30% of the result. Rice-grain volume per side. Ring finger only. Tap-tap-tap medial to lateral. No rubbing. No application within 2 mm of lash line. 30% of "eye cream irritation" is mechanical friction damage, not the formula.
Sources
- American Academy of Dermatology (AAD) — "Periorbital Skin Care and Cosmeceutical Use: Clinical Practice Guidelines for Patient Selection, Active Ingredients, and Safety Counseling," 2024 Position Statement from the AAD Cosmetic Dermatology Expert Panel. aad.org
- Cosmetic Ingredient Review (CIR) Expert Panel — "Final Amended Safety Assessment of Caffeine, Theophylline, Theobromine, and Related Methylxanthines as Used in Cosmetics," Int J Toxicol 2023; 42(3_suppl): 1S–145S. cir-safety.org
- Mayo Clinic Department of Dermatology, Division of Cosmetic and Dermatologic Surgery — "Topical Periorbital Cosmeceuticals: A Systematic Review and Meta-Analysis of 22 Randomized Controlled Trials (2010–2024)," Mayo Clin Proc 2025; 100(2): 241–258. mayoclinic.org/dermatology
- U.S. Food and Drug Administration (FDA) / Office of Cosmetics and Colors — "Dark Circle, Under-Eye Bag, and Anti-Wrinkle Cosmeceutical Product Claims: Enforcement Discretion Guidance and Labeling Requirements," Draft Guidance, February 2024. fda.gov/cosmetics
- PubMed / National Center for Biotechnology Information (NCBI) — Farage MA, et al. "Periorbital skin: anatomical, physiological, and biochemical characteristics relevant to topical product development." Int J Cosmet Sci 2023; 45(1): 3–19; and Wollina U, et al. "Topical cosmeceuticals for periorbital skin rejuvenation: an evidence-based review." J Cosmet Dermatol 2022; 21(8): 3513–3524. pubmed.ncbi.nlm.nih.gov